
Tyra Biosciences (TYRA) Stock Forecast & Price Target
Tyra Biosciences (TYRA) Analyst Ratings
Bulls say
Tyra Biosciences is a promising investment with its clinical-stage biotechnology platform, SNAP, and its focus on precision medicines for oncology and genetically defined conditions. The potential for success in their product pipeline, particularly dabogratinib for non-muscle invasive bladder cancer, is high due to promising results and high unmet need in the market. Additionally, the company's target price of $54 per share and lack of competition in this specific market make it a strong investment opportunity.
Bears say
Tyra Biosciences is a biotechnology company with a negative outlook due to concerns about its drug candidate, dabogratinib, and its potential for limited efficacy and safety issues. While the company's precision medicine platform and drug candidates show promise, there are risks associated with launching a new drug and competition in the market. Additionally, there are concerns about the potential recurrence rates in patients with the targeted conditions and the limitations of current treatments. The company's recent data on dabogratinib also raises some red flags, and there are doubts about its ability to effectively compete with other approved drugs.
This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Tyra Biosciences (TYRA) Analyst Forecast & Price Prediction
Start investing in Tyra Biosciences (TYRA)
Order type
Buy in
Order amount
Est. shares
0 shares